By Ben Butkus

Life Technologies this week announced the expansion of its TaqMan Mutation Detection Assays based on competitive allele-specific TaqMan, or Cast, PCR technology.

The company now offers TaqMan Mutation Detection Assays for 241 of the most common mutations in 21 important cancer genes on top of the company's previous commercial assays, introduced about a year ago, for detecting mutations in the KRAS, BRAF, and EGFR genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.